Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track FATE with free AI briefings, catalyst countdowns, and dilution alerts.

FATE · FATE THERAPEUTICS INC

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$139.1M Cash on Hand
15mo Cash Runway
Follow FATE by email Get an email when FATE reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about FATE, unsubscribe in one click. Privacy

📣 What FATE Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
ProHema-CB Hematologic Malignancies Phase 2 · NCT01627314 Terminated
iPSC-derived Allogeneic Anti-CD19 1XX-CAR… Lupus Nephritis Phase 2 · NCT07570862 Recruiting
FT839 ANCA-Associated Vasculitis (AAV) Phase 1/2 · NCT07800871 Recruiting
ProTmune Hematologic Malignancies Phase 1/2 · NCT02743351 Completed
Control Hematologic Malignancies Phase 1/2 · NCT02743351 Completed
Untreated CB Hematologic Malignancies Phase 2 · NCT01627314 Terminated
Vincristine Diffuse Large B Cell Lymphoma Phase 1 · NCT05934097 Withdrawn
iPSC-derived Allogeneic Anti-HER2 CAR T-cells… Advanced Solid Tumor Phase 1 · NCT06241456 Recruiting
Allogeneic iPSC-derived CD58KO Anti-MICA/MICB… Non-Small Cell Lung Cancer Phase 1 · NCT07216105 Recruiting
Melphalan Hematologic Malignancies Phase 1 · NCT00890500 Completed
iPSC-derived CD16/IL-15RF-expressing Anti-CD19… Lymphoma, B-Cell Phase 1 · NCT04245722 Terminated
ProHema-CB Transplant Metabolic Disorders Phase 1 · NCT02354443 Terminated
Single FT1050 treated UCB unit Non-Hodgkin's Lymphoma (NHL) Phase 1 · NCT01527838 Completed
Doxorubicin Diffuse Large B Cell Lymphoma Phase 1 · NCT05934097 Withdrawn
Bendamustine Advanced Solid Tumor Phase 1 · NCT06241456 Recruiting
Biological: ProHema-CB Hematologic Malignancies Phase 1 · NCT02354417 Terminated

Also used in these trials (approved or third-party drugs, not FATE's own candidates): Pembrolizumab, Interleukin-2, Nivolumab, Obinutuzumab, Sirolimus, Prednisone, Trastuzumab, Rituximab, Tacrolimus Extended-Release, Atezolizumab, Avelumab, Cetuximab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

FATE holds $139.1M in cash and short-term investments (as of Sep 30, 2026) and burns about $27.8M/quarter from operations, an estimated runway of 15 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 43 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when FATE files for a raise →

👥 Who Owns FATE

Insiders 24.8% Institutions (186 holders) 69.1% Public and other holders 6.1%
HolderTypeShares% of sharesAs of
Redmile Group, LLC
Director, 10% owner · +7.80M options
Insider 19,164,572 15.76% 2026-11-05
RedCo II Master Fund, L.P.
Director, 10% owner
Insider 8,977,624 7.38% 2025-07-02
William H Rastetter
Director · +142,900 options
Insider 642,424 0.53% 2026-05-05
Bahram Valamehr
President and CEO, Director · +1.30M options
Insider 591,815 0.49% 2026-08-04
Cindy Tahl
Chief Legal and Compliance Officer · +508,336 options
Insider 589,355 0.48% 2026-08-04
Kamal Adawi
Chief Financial Officer · +450,000 options
Insider 93,418 0.08% 2026-11-03
Robert S Epstein
Director · +142,900 options
Insider 36,331 0.03% 2026-05-05

Share count 121,568,755 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full FATE picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for FATE and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.